Key facts
- It has raised $20.0M; the latest was Early Stage VC in Jan 2026.
- Notable investors include Lapam Capital, Shanghai Healthcare Capital, Cherami Investment Group, LAV (Lilly Asia Fund), Pivotal BioVenture Partners (China) — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for NeuShen Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for NeuShen Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About NeuShen Therapeutics
Developer of therapeutic compounds and gene-based delivery systems designed for the treatment of psychiatric and neurological disorders. The company offers small molecule discovery with AAV-based gene therapy, thereby enabling the biopharmaceutical market to address complex central nervous system conditions through targeted mechanisms, scalable clinical development, and a dual-modality approach that supports both precision medicine and broad therapeutic applicability.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2021
- Website
- cn.neushen.com/
- Ownership
- Privately Held (backing)
NeuShen Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in NeuShen Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on NeuShen Therapeutics in its N-PORT filings yet. We sweep new filings monthly.